Jazz Pharma to buy GW Pharma for $7.2 bln, adding cannabis-based drug to portfolio
Jazz Pharma to buy GW Pharma for $7.2 bln, adding cannabis-based drug to portfolio By Ankur Banerjee, Shariq Khan and Rebecca Spalding Reuters (Reuters) - Jazz Pharmaceuticals Plc said on Wednesday it had agreed to buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal which will bolster its neuroscience business with the addition of a cannabis-based epilepsy treatment. GW Pharma's Epidiolex, the first marijuana-derived drug to be approved in the U.S., generated sales of over $500 million for the U.K.-based company last year. Analysts expect sales to breach $1 billion soon. The ...
Source: netscape.com